Cancer Treatment Reviews
Volume 35, Issue 7 , Pages 540-546 , November 2009

Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: A systematic review and meta-analysis of randomised trials

  • M.D. Shelley

      Affiliations

    • Cochrane Urological Cancers Unit, Research Department, Velindre NHS Trust, Cardiff CF14 2TL, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 029 20 316909; fax: +44 029 20 529625.
    • ,
  • S. Kumar

      Affiliations

    • Department of Oncology, Velindre NHS Trust, Cardiff CF14 2TL, UK
    • Tel.: +44 029 20 615888; fax: +44 029 20 316267.
    • ,
  • B. Coles

      Affiliations

    • Cardiff Information Service, Cardiff University, Velindre NHS Trust, Cardiff CF14 2TL, UK
    • Tel.: +44 029 20 316291; fax: +44 029 20 521609.
    • ,
  • T. Wilt

      Affiliations

    • Cochrane Prostate Diseases and Urologic Cancers Group, VA Centre for Chronic Disease Outcomes Research, Minneapolis, MN 55417, USA
    • Tel.: +1 612 467 2681; fax: +1 612 467 2118.
    • ,
  • J. Staffurth

      Affiliations

    • Cardiff University, School of Medicine, Research Department, Velindre NHS Trust, Cardiff CF14 2TL, UK
    • Tel.: +44 029 2061 5888x6353; fax: +44 029 2052 9625.
    • ,
  • M.D. Mason

      Affiliations

    • Cardiff University, School of Medicine, Research Department, Velindre NHS Trust, Cardiff CF14 2TL, UK
    • Tel.: +44 029 20 316964; fax: +44 029 20 529625.

Received 23 February 2009 ,Revised 5 May 2009 ,Accepted 6 May 2009.

References 

  1. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother. 1966;50:125–128
  2. van den Ouden D, Hop WCJ, Kranse R, Schroder FH. Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localised carcinoma of the prostate. Brit J Urol. 1997;79:203–211
  3. Connolly SS, O’Tool GC, O’Malley KJ. Positive surgical apical surgical margins after radical prostatectomy truth or artifact?. Scand J Urol Nephrol. 2004;38:26–32
  4. Harnden P, Shelley MD, Clements H, et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer. 2007;109:13–24
  5. Huggins C, Hodges CV. Studies on prostate cancer 1: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–297
  6. Harisiadis LR, Veenema J, Senszyn JJ, et al. Carcinoma of the prostate. Cancer. 1978;41:2131–2142
  7. Rosen EM, Cassady RJ, Connolly J, Chaffey JT. Radiotherapy for localised prostate carcinoma. Int J Radiat Oncol Biol Phys. 1984;18:3201–3210
  8. Perez CA, Pilepich MV, Zivnuska F. Tumour control in definitive irradiation of localised carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1986;13:523–531
  9. Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys. 1988;14(6):1085–1091
  10. Beyer A, Lettenberg A, Attwein JE. Adjuvant hormonal therapy following radical prostatectomy. Eur Urol. 1993;24(2):51–56
  11. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New Engl J Med. 1999;341(24):1781–1788
  12. Wirth MP, Weissbach L, Marx FJ, et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol. 2004;45(3):267–270
  13. McLeod DG, Iversen P, See WA, et al. Bicalutamide 150mg plus standard care vs standard care alone for early prostate cancer. BJU Int. 2006;97(2):247–254
  14. DerSimonian R, Laird LN. Meta-analysis of clinical trials. Control Clin Trials. 1986;7:177–188
  15. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–106
  16. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys. 2005;61(5):1285–1290
  17. Tyrrell CJ, Payne H, See WA, et al. Bicalutamide (‘Casodex’) 150mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol. 2005;76(1):4–10
  18. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472–479
  19. Parker C, Sydes M, Catton C, et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int. 2007;99:1376–1379

PII: S0305-7372(09)00081-4

doi: 10.1016/j.ctrv.2009.05.001

Cancer Treatment Reviews
Volume 35, Issue 7 , Pages 540-546 , November 2009

Article Tools

* Image Usage & Resolution